Sugi Predict

Sugi Predict / Compounds / SCHEMBL2560869

SCHEMBL2560869

SCHEMBL2560869

O=CCCN1CCCC1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 1/20 0.47
▸ KMT2A Q03164 4/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ PKM P14618 1/20 0.46
▸ TSHR P16473 4/20 0.46
▸ CHRM2 P08172 2/20 0.43
▸ CHRM5 P08912 2/20 0.43
▸ CYP2D6 P10635 2/20 0.43
▸ CHRM1 P11229 2/20 0.43
▸ CHRM3 P20309 2/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CHRM4 P08173 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ BRD4 O60885 1/20 0.41
▸ BRD2 P25440 1/20 0.41
▸ ADRA1D P25100 1/20 0.40
▸ ADRA1A P35348 1/20 0.40
▸ ADRA1B P35368 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2559744 0.94 L3MBTL1 (0.43) PIK3CDKMT2AMEN1PKMTSHR
SCHEMBL2555170 0.92 L3MBTL1 (0.46) PIK3CDKMT2AMEN1PKMTSHR
SCHEMBL7323646 0.88 KMT2A (0.44) PIK3CDKMT2AMEN1PKMTSHR
SCHEMBL261644 0.82 PIK3CD (0.58) PIK3CDKMT2AMEN1PKMTSHR
SCHEMBL17688552 0.82 PIK3CD (0.50) PIK3CDKMT2AMEN1PKMTSHR
SCHEMBL2451758 0.82 PIK3CD (0.46) PIK3CDKMT2AMEN1PKMTSHR
SCHEMBL4870239 0.81 L3MBTL1 (0.44) PIK3CDKMT2AMEN1PKMTSHR
SCHEMBL1305598 0.79 KMT2A (0.53) PIK3CDKMT2AMEN1PKMTSHR
SCHEMBL1981275 0.78 — —
SCHEMBL5424673 0.78 PIK3CD (0.54) PIK3CDKMT2AMEN1PKMTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10787484-B2 Compositions and methods for treating cardiovascular disease GENENTECH, INC. (US) 2020-09-29 — — US claimed
CN-106715528-B The eugenol polyethers of hydrosilylation and the preparation of eugenol polyether silicone and application thereof 赢创德固赛有限公司 2019-08-23 — — CN claimed
US-20190177366-A1 COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE GENENTECH, INC. (US) 2019-06-13 — — US claimed
CN-112341521-B Small molecule active compound and antibody conjugate thereof, preparation method and medical application thereof 上海翰森生物医药科技有限公司 2024-06-25 — — CN disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 — — US disclosed
US-11225655-B2 Bi-functional complexes and methods for making and using such complexes NUEVOLUTION A/S (DK) 2022-01-18 — — US disclosed
US-11034725-B2 Compositions and methods for treating cardiovascular disease GENENTECH, INC. (US) 2021-06-15 — — US disclosed
CN-112341521-A Small molecule active compound and antibody conjugate thereof, preparation method and medical application thereof 上海翰森生物医药科技有限公司 2021-02-09 — — CN disclosed
US-10787484-B2 Compositions and methods for treating cardiovascular disease GENENTECH, INC. (US) 2020-09-29 — — US disclosed
US-20200283478-A1 COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE GENENTECH, INC. (US) 2020-09-10 — — US disclosed
EP-3540059-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES Nuevolution A/S (DK) 2019-09-18 — — EP disclosed
EP-1720856-B1 HIV INTEGRASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-08-14 — — EP disclosed
EP-2558577-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES Nuevolution A/S (DK) 2013-02-20 — — EP disclosed
WO-2011127933-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2011-10-20 — — WO disclosed
US-20070124152-A1 Hiv Integrase Inhibitors GLAXOSMITHKLINE LLC 2007-05-31 — — US disclosed
EP-0303689-A4 EPOXY PYRROLIDONE BASED NON-IONIC SURFACTANTS — 1990-09-12 — — EP disclosed
US-4831159-A RHODIUM COMPLEX SELECTIVE CATALYST TEXACO INC. (US) 1989-05-16 — — US disclosed
EP-0303689-A1 EPOXY PYRROLIDONE BASED NON-IONIC SURFACTANTS GAF CHEMICALS CORPORATION (US) 1989-02-22 — — EP disclosed
US-4801400-A POLYETHERS GAF CORPORATION (US) 1989-01-31 — — US disclosed
WO-1988006586-A1 EPOXY PYRROLIDONE BASED NON-IONIC SURFACTANTS GAF CORPORATION (US) 1988-09-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200283478-A1 COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE PCSK9, PCSK7, PCSK6 PIK3CD 518/4885KMT2A 2277/4885MEN1 1924/4885
US-11034725-B2 Compositions and methods for treating cardiovascular disease PCSK9, PCSK7, PCSK6 PIK3CD 518/4885KMT2A 2277/4885MEN1 1924/4885
US-10787484-B2 Compositions and methods for treating cardiovascular disease PCSK9, PCSK7, PCSK6 PIK3CD 518/4885KMT2A 2277/4885MEN1 1924/4885
US-20190177366-A1 COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE PCSK9, PCSK7, PCSK6 PIK3CD 518/4885KMT2A 2277/4885MEN1 1924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.